Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders

Journal of Psychopharmacology October 1, 2017 Cameron Castle, Andrew Gray, Shona Neehoff et al. 20 citations

Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose. The most commonly used instrument to assess this is the Clinician-Administered Dissociative States Scale (CADSS), developed based on the assessment of patients with dissociative symptoms. Its psychometric properties for ketamine-induced dissociation have not been...

Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.

Journal of Psychopharmacology October 2017 Paul Glue, Natalie J. Medlicott, Sarah Harland et al.

The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of...

Serotonin and brain function: a tale of two receptors.

Journal of Psychopharmacology August 31, 2017 R L Carhart-Harris, D J Nutt

Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and...

Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.

Journal of Psychopharmacology August 1, 2017 Mark T Wagner, Michael C Mithoefer, Ann T Mithoefer et al. 163 citations

A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. There is evidence that lasting changes in the personality feature of "openness"...

Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects.

Journal of Psychopharmacology August 2017 Andrew C. Parrott, Luke A. Downey, Carl A Roberts et al.

The purpose of this article is to debate current understandings about the psychobiological effects of recreational 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'), and recommend theoretically-driven topics for future research. Recent empirical findings, especially those from novel topic areas were reviewed. Potential causes for the high variance often found in group findings were also...

DOI: 10.1177/0269881117711922 (opens in new tab) Full text (opens in new tab) Ecstasy 3,4-methylenedioxymethamphetamine Central nervous system Cognition +3

Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves

Journal of Psychopharmacology July 10, 2017 Sarah Saleemi, Steven Pennybaker, Missi Wooldridge et al. 97 citations

Methylenedioxymethamphetamine (MDMA), often sold as ‘Ecstasy’ or ‘Molly’, is commonly used at music festivals and reported to be responsible for an increase in deaths over the last decade. Ecstasy is often adulterated and contains compounds that increase morbidity and mortality. While users and clinicians commonly assume that products sold as Molly are less-adulterated MDMA products, this has...

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness

Journal of Psychopharmacology June 20, 2017 Matthias Forstmann, Christina Sagioglou 153 citations

In a large-scale ( N = 1487) general population online study, we investigated the relationship between past experience with classic psychedelic substances (e.g. LSD, psilocybin, mescaline), nature relatedness, and ecological behavior (e.g. saving water, recycling). Using structural equation modeling we found that experience with classic psychedelics uniquely predicted self-reported engagement...

Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.

Journal of Psychopharmacology June 2017 Richard C. Kevin, Katie E Wood, Jordyn Stuart et al.

Synthetic cannabinoids (SCs) have rapidly proliferated as recreational drugs, and may present a substantial health risk to vulnerable populations. However, information on possible effects of long-term use is sparse. This study compared acute and residual effects of the popular indazole carboxamide SC compounds AB-PINACA and AB-FUBINACA in adolescent rats with ∆9-tetrahydrocannabinol (THC) and...

DOI: 10.1177/0269881116684336 (opens in new tab) Full text (opens in new tab) Ab-fubinaca Ab-pinaca Cannabinoid Adolescent +2

The association of psychedelic use and opioid use disorders among illicit users in the United States.

Journal of Psychopharmacology May 2017 Vincent D Pisano, Nathaniel P Putnam, Hannah M. Kramer et al.

Preliminary studies show psychedelic compounds administered with psychotherapy are potentially effective and durable substance misuse interventions. However, little is known about the association between psychedelic use and substance misuse in the general population. This study investigated the association between psychedelic use and past year opioid use disorders within illicit opioid users....

Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies

Journal of Psychopharmacology April 3, 2017 Kim P. C. Kuypers, Patrick C. Dolder, Johannes G. Ramaekers et al. 88 citations

Previous placebo-controlled experimental studies have shown that a single dose of MDMA can increase emotional empathy in the multifaceted empathy test (MET) without affecting cognitive empathy. Although sufficiently powered to detect main effects of MDMA, these studies were generally underpowered to also validly assess contributions of additional parameters, such as sex, drug use history, trait...

Safety pharmacology of acute MDMA administration in healthy subjects

Journal of Psychopharmacology February 21, 2017 Patrick Vizeli, Matthias E. Liechti 142 citations

3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-assisted psychotherapy. The present study characterized the safety pharmacology of single-dose administrations of MDMA (75 or 125 mg) using data from nine double-blind, placebo-controlled, crossover studies performed in the same laboratory in a total of 166 healthy subjects. The duration of the subjective effects...

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Journal of Psychopharmacology January 18, 2017 Matthew W. Johnson, Albert Garcia‐romeu, Patrick S. Johnson et al. 129 citations

Data suggest psychedelics such as psilocybin and lysergic acid diethylamide (LSD) may hold therapeutic potential in the treatment of addictions, including tobacco dependence. This retrospective cross-sectional anonymous online survey characterized 358 individuals (52 females) who reported having quit or reduced smoking after ingesting a psychedelic in a non-laboratory setting ⩾1 year ago. On...

DOI: 10.1177/0269881116684335 (opens in new tab) Smoking cessation Tobacco use Clinical psychology Naturalistic observation +1

Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users.

Journal of Psychopharmacology December 2016 Lewis Jones, Phil Reed, Andrew C. Parrott

The purpose of this study was to compare the effects of mephedrone and 3,4-methylenedioxy-methamphetamine (MDMA), as reported by young recreational polydrug users. 152 MDMA users and 81 mephedrone users were recruited through snowballing on social network sites. They completed a standard online questionnaire for either mephedrone or MDMA. The questions covered the average amount taken per...

DOI: 10.1177/0269881116653106 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxy-methamphetamine Mephedrone Cathinone Entactogen +1

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Journal of Psychopharmacology November 30, 2016 Annie Umbricht, Mary P Cosimano, Roland R. Griffiths et al. 2,174 citations

Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the...

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Journal of Psychopharmacology November 30, 2016 Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al. 1,699 citations

Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were...

DOI: 10.1177/0269881116675512 (opens in new tab) Anxiety Depression Cancer Psychedelic therapy psilocybin +6

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Journal of Psychopharmacology November 18, 2016 Frederick S. Barrett, Matthew P. Bradstreet, Jeannie‐marie Leoutsakos et al. 364 citations

Acute adverse psychological reactions to classic hallucinogens (“bad trips” or “challenging experiences”), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood),...

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Journal of Psychopharmacology November 18, 2016 James Rucker, Luke A. Jelen, Sarah Kalen Flynn et al. 187 citations

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used...

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology

Journal of Psychopharmacology November 16, 2016 Ido Hartogsohn 469 citations

Placebo response theory and set and setting theory are two fields which examine how non-biological factors shape the response to therapy. Both consider factors such as expectancy, preparation and beliefs to be crucial for understanding the extra-pharmacological processes which shape the response to drugs. Yet there are also fundamental differences between the two theories. Set and setting...

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.

Journal of Psychopharmacology November 15, 2016 Clinton E. Canal, Kevin S. Murnane

Classic hallucinogens share pharmacology as serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptor agonists. Unique among most other Schedule 1 drugs, they are generally non-addictive and can be effective tools in the treatment of addiction. Mechanisms underlying these attributes are largely unknown. However, many preclinical studies show that 5-HT 2C agonists counteract the addictive effects of...

Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use

Journal of Psychopharmacology September 6, 2016 Helle Ruff Laursen, Susanne Henningsson, Julian Macoveanu et al. 8 citations

The brain’s serotonergic system plays a crucial role in the processing of emotional stimuli, and several studies have shown that a reduced serotonergic neurotransmission is associated with an increase in amygdala activity during emotional face processing. Prolonged recreational use of ecstasy (3,4-methylene-dioxymethamphetamine [MDMA]) induces alterations in serotonergic neurotransmission that...

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Journal of Psychopharmacology August 31, 2016 Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett et al. 541 citations

Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most...

The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Journal of Psychopharmacology August 26, 2016 Anya K. Bershad, Melissa A. Miller, Matthew J. Baggott et al. 104 citations

±3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that enhances sociability and feelings of closeness with others. These “prosocial” effects appear to motivate the recreational use of MDMA and may also form the basis of its potential as an adjunct to psychotherapy. However, the extent to which MDMA differs from prototypic stimulant drugs, such as dextroamphetamine,...

Neurocognitive performance following acute mephedrone administration, with and without alcohol

Journal of Psychopharmacology August 25, 2016 EB de Sousa Fernandes Perna, Esther Papaseit, Clara Pérez‐mañá et al. 26 citations

Recreational use of mephedrone, alone and in combination with alcohol, has increased over the past years. Pharmacological properties of mephedrone share similarities with methylenedioxymethamphetamine (MDMA), but its effect on neurocognitive function has not been well established in humans. The present study assessed the effect of mephedrone alone and after co-administration with alcohol on...

DOI: 10.1177/0269881116662635 (opens in new tab) Mephedrone Neurocognitive Placebo Psychomotor learning +5

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of Psychopharmacology July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 (opens in new tab) Full text (opens in new tab) Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats.

Journal of Psychopharmacology July 2016 Sinead E Shortall, Alfred Richard Green, Kevin Cf Fone et al.

Administration of caffeine with 3,4-methylenedioxymethamphetamine (MDMA) alters the pharmacological properties of MDMA in rats. The current study examined whether caffeine alters the behavioural and neurochemical effects of mephedrone, which has similar psychoactive effects to MDMA. Rats received either saline, mephedrone (10 mg/kg), caffeine (10 mg/kg) or combined caffeine and mephedrone...